Hemogenyx Pharmaceuticals PLC HOPHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HOPHF is a good fit for your portfolio.
News
-
Hemogenyx Pharmaceuticals PLC Announces Final Results
-
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
-
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 million
-
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery
-
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
-
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
-
Hemogenyx Pharmaceuticals Says FDA Accepted Plans to Address Leukemia Treatment Concerns
-
Hemogenyx Pharmaceuticals Addresses FDA Concern on Leukemia Treatment; Shares Rise
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.04–0.04
- 52-Week Range
- $0.04–0.20
- Bid/Ask
- $0.00 / $1.00
- Market Cap
- $45.68 Mil
- Volume/Avg
- 125,000 / 125,000
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.hemogenyx.com
Valuation
|
Metric
|
HOPHF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.88 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HOPHF
|
|---|---|
Quick Ratio | 4.07 |
Current Ratio | 4.07 |
Interest Coverage | −43.63 |
Quick Ratio
HOPHF
Profitability
|
Metric
|
HOPHF
|
|---|---|
Return on Assets (Normalized) | −94.82% |
Return on Equity (Normalized) | −198.45% |
Return on Invested Capital (Normalized) | −96.81% |
Return on Assets
HOPHF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yctrpmmt | Sffr | $547.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wgmgncc | Xjgpwf | $105.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tqqrkltx | Rbfgfb | $103.7 Bil | |
MRNA
| Moderna Inc | Bkctcxrwz | Kgnt | $47.9 Bil | |
ARGX
| argenx SE ADR | Yncbnjzd | Xmmpd | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Lfkwzrn | Brqck | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Smqbtns | Rxklxl | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ksvzlrtx | Jzkrtwg | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rzjyrpnsd | Gpzmywc | $12.8 Bil | |
INCY
| Incyte Corp | Gtsgfkvcc | Nwqlj | $12.1 Bil |